Polycystic Kidney Disease Treatment & Management

  • Author: Roser Torra, MD, PhD; Chief Editor: Vecihi Batuman, MD, FACP, FASN   more...
 
Updated: Oct 5, 2011
 

Approach Considerations

Pharmacologic therapy is necessary to accomplish the following:

  • Control blood pressure
  • Control abnormalities related to renal failure
  • Treat urinary tract infections
  • Treat hematuria
  • Reduce abdominal pain produced by enlarged kidneys

Patients with autosomal dominant polycystic kidney disease (ADPKD) who progress to end-stage renal disease may require hemodialysis, peritoneal dialysis, or renal transplantation. For more information, see the Medscape Reference articles Chronic Kidney Disease and Renal Transplantation.

In patients with heart murmurs, institute routine American Heart Association antibiotic prophylaxis.

A study by Torres et al identified serum high-density lipoprotein (HDL) cholesterol, urine sodium excretion (UNa V), and 24-hour osmolality as having a likely effect on ADPKD progression.[24] Whether modification of these components influences the clinical course of ADPKD remains unclear.

Several classes of drugs have been identified as having potential benefit in ADPKD (eg, vasopressin-2-receptor antagonists, mammalian targets of rapamycin [mTOR] inhibitors).[25, 26] Clinicians may wish to refer patients for inclusion of clinical trials.[27, 28]

Metabolic problems related to renal failure that need to be controlled include the following:

Diet and activity

Although a low-salt diet is recommended when hypertension or renal failure is present, no other special diet reportedly is of benefit.

Patients should avoid contact sports in which direct trauma to the back or abdomen is likely. This is especially important with larger, palpable kidneys in order to minimize the risk of rupture.

Next

Blood Pressure Control

In patients with renal disease, the goal is a blood pressure of less than 130/88 mm Hg. If more than 1 g/day of urinary protein is present, the target blood pressure is less than 125/75 mm Hg. Achieving good blood pressure control helps slow the progression of renal disease.[29] A study by Patch et al showed that when intensity and coverage of antihypertensive therapy were increased, mortality decreased for patients with ADPKD.[30]

The drugs of choice for this condition are angiotensin-converting enzyme (ACE) inhibitors (ie, captopril, enalapril, lisinopril) or angiotensin II receptor blockers (ARBs) such as telmisartan, losartan, irbesartan, and candesartan. These agents remain the most recommended drugs to treat hypertension in patients with ADPKD, although studies of the renin-angiotensin-aldosterone system have not convincingly demonstrated that it plays an important role in its pathogenesis. Calcium channel blockers are not recommended.

In patients with advanced renal disease, ACE inhibitors and ARBs can exacerbate renal failure or increase serum potassium levels; therefore, regularly monitor use with serum chemistry values.

Previous
Next

Infectious and Other Disorders

Urinary tract infections (UTIs) occur in 30-50% of ADPKD patients and most frequently in women. Gram-negative bacteria are the most common pathogens.

Distinguishing between infections of the bladder, renal parenchyma, and cysts is important because the treatment for each condition is different. Treating infected cysts requires antibiotics that penetrate into the cyst. Useful agents are ciprofloxacin, trimethoprim-sulfamethoxazole, clindamycin, and chloramphenicol.

Hematuria

Hematuria is frequent in patients with ADPKD. It usually results from cyst rupture or stone passage. Instruct the patient to drink large amounts of water, to rest, and to take a pain killer if necessary. Hematuria is usually self-limited. Hospitalization is necessary if the patient is still bleeding after several days or if the amount of blood is substantial.

Abdominal pain from enlarged kidneys

Avoid nonsteroidal anti-inflammatory drugs (NSAIDs), because they can worsen renal function and potentiate hyperkalemia. Treatment involves surgical cyst decompression which is effective for pain relief in 60-80% of patients. See Surgical Drainage, below.

Previous
Next

Surgical Drainage

If infected renal or hepatic cysts do not respond to conventional antibiotic therapy, surgical drainage may be necessary. This procedure is usually performed with ultrasonographically guided puncture.[31]

Cysts may become large enough to cause abdominal discomfort or pain. Typically, acute pain is from cyst hemorrhage or an obstruction by a clot, stone, or infection.[32] When one or more cysts can be identified as causing the pain, the symptoms can often be abated by open- or fiberoptic–guided surgery to excise the outer walls and to drain them.

Approximately 25% of patients with the most severe pain do not gain relief from surgery or pharmacologic therapy with narcotics. These individuals usually have inaccessible cysts in the medullary portions of the kidneys. Nephrectomy is used as a last resort to control the pain in these patients. Nephrectomy is often necessary when there is not enough room for a kidney graft.

Severe polycystic liver disease can result in massive hepatomegaly (see image below). When the liver becomes so large that it prevents the patient from obtaining normal nutrition or causes severe abdominal discomfort, a surgical procedure is necessary. Surgical intervention may range from unroofing several cysts to a partial hepatectomy.

Polycystic kidney disease and massive polycystic lPolycystic kidney disease and massive polycystic liver disease.

Partial hepatectomy is difficult because of the characteristics of the polycystic liver. Only very expert surgeons should proceed with this surgical procedure.

When the polycystic liver causes portal hypertension or is very large with nonresectable areas, liver transplantation may be necessary.

Special attention should be paid when bilateral nephrectomy has to be carried out in patients with severe liver involvement. Several cases of refractory ascites after bilateral nephrectomy have been reported in these patients.

Previous
Next

Consultations and Long-Term Monitoring

Consultations may be indicated under the following circumstances:

  • Nephrologist upon evidence of renal insufficiency, hypertension, microalbuminuria, or concentrating defect
  • Invasive radiologist for cyst sclerosis or drainage
  • General surgeon for nephrectomy, cyst decompression, unroofing, or surgical hepatic procedures
  • Neurosurgeon for ICAs
  • Cardiologist for valvular abnormalities

Ensure that a patient with ADPKD who is nonhypertensive and has normal renal function undergoes blood testing and ultrasonography of the kidneys every 1-2 years.

Schedule more frequent follow-up studies for patients with high blood pressure. Hypertension is common, occurring in as many as 50-70% of patients before the onset of renal failure.

Patients with renal failure require more frequent monitoring, based on the severity of their condition.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Roser Torra, MD, PhD  Consulting Staff, Hereditary Renal Diseases, Department of Nephrology, Fundacio Puigvert, Spain

Roser Torra, MD, PhD is a member of the following medical societies: American Society of Nephrology and International Society of Nephrology

Disclosure: Nothing to disclose.

Specialty Editor Board

Laura Lyngby Mulloy, DO, FACP  Professor of Medicine, Chief, Section of Nephrology, Hypertension, and Transplantation Medicine, Glover/Mealing Eminent Scholar Chair in Immunology, Medical College of Georgia

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

George R Aronoff, MD  Director, Professor, Departments of Internal Medicine and Pharmacology, Section of Nephrology, Kidney Disease Program, University of Louisville School of Medicine

George R Aronoff, MD is a member of the following medical societies: American Federation for Medical Research, American Society of Nephrology, Kentucky Medical Association, and National Kidney Foundation

Disclosure: Nothing to disclose.

Chief Editor

Vecihi Batuman, MD, FACP, FASN  Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Medicine Service, Southeast Louisiana Veterans Health Care System

Vecihi Batuman, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, and International Society of Nephrology

Disclosure: Nothing to disclose.

References
  1. Wilson PD. Polycystic kidney disease. N Engl J Med. Jan 8 2004;350(2):151-64. [Medline].

  2. Pirson Y. Extrarenal Manifestations of Autosomal Dominant Polycystic Kidney Disease. Adv Chronic Kidney Dis. Mar 2010;17(2):173-180. [Medline].

  3. Tufan F, Uslu B, Cekrezi B, Uysal M, Alpay N, Turkmen K, et al. Assessment of Adrenal Functions in Patients with Autosomal Dominant Polycystic Kidney Disease. Exp Clin Endocrinol Diabetes. Feb 9 2010;[Medline].

  4. Torres VE. Vasopressin antagonists in polycystic kidney disease. Kidney Int. Nov 2005;68(5):2405-18. [Medline]. [Full Text].

  5. Ong AC, Wheatley DN. Polycystic kidney disease--the ciliary connection. Lancet. Mar 1 2003;361(9359):774-6. [Medline].

  6. Rossetti S, Harris PC. Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease. J Am Soc Nephrol. May 2007;18(5):1374-80. [Medline].

  7. Qian F, Watnick TJ, Onuchic LF, et al. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell. Dec 13 1996;87(6):979-87. [Medline].

  8. Fary Ka E, Seck SM, Niang A, et al. Patterns of autosomal dominant polycystic kidney diseases in black Africans. Saudi J Kidney Dis Transpl. Jan 2010;21(1):81-6. [Medline].

  9. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. Jan 2006;1(1):148-57. [Medline].

  10. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. May 18 2006;354(20):2122-30. [Medline]. [Full Text].

  11. Idrizi A, Barbullushi M, Petrela E, et al. The influence of renal manifestations to the progression of autosomal dominant polycystic kidney disease. Hippokratia. Jul 2009;13(3):161-4. [Medline]. [Full Text].

  12. Hateboer N, v Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. Jan 9 1999;353(9147):103-7. [Medline].

  13. Torra R, Badenas C, Darnell A, et al. Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J Am Soc Nephrol. Oct 1996;7(10):2142-51. [Medline].

  14. Chauveau D, Pirson Y, Verellen-Dumoulin C, et al. Intracranial aneurysms in autosomal dominant polycystic kidney disease. Kidney Int. Apr 1994;45(4):1140-6. [Medline].

  15. Rahman E, Niaz FA, Al-Suwaida A, et al. Analysis of causes of mortality in patients with autosomal dominant polycystic kidney disease: A single center study. Saudi J Kidney Dis Transpl. Sep-Oct 2009;20(5):806-10. [Medline].

  16. Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. Sep 2009;20(9):1888-93. [Medline].

  17. Cadnapaphornchai MA, McFann K, Strain JD, et al. Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol. Apr 2009;4(4):820-9. [Medline].

  18. Pei Y. Diagnostic approach in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. Sep 2006;1(5):1108-14. [Medline].

  19. Sawicki M, Walecka A, Rozanski J, et al. Doppler sonography measurements of renal vascular resistance in autosomal-dominant polycystic kidney disease. Med Sci Monit. Aug 2009;15(8):MT101-4. [Medline].

  20. Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. Apr 2 1994;343(8901):824-7. [Medline].

  21. Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. Jan 2009;20(1):205-12. [Medline]. [Full Text].

  22. Huston J 3rd, Torres VE, Wiebers DO, et al. Follow-up of intracranial aneurysms in autosomal dominant polycystic kidney disease by magnetic resonance angiography. J Am Soc Nephrol. Oct 1996;7(10):2135-41. [Medline].

  23. Irazabal MV, Huston J 3rd, Kubly V, Rossetti S, Sundsbak JL, Hogan MC, et al. Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. Jun 2011;6(6):1274-85. [Medline]. [Full Text].

  24. Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF Jr, et al. Potentially Modifiable Factors Affecting the Progression of Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. Mar 2011;6(3):640-647. [Medline].

  25. Masoumi A, Reed-Gitomer B, Kelleher C, et al. Potential pharmacological interventions in polycystic kidney disease. Drugs. 2007;67(17):2495-510. [Medline].

  26. Walz G. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?. Nephrol Dial Transplant. Jul 2006;21(7):1752-7. [Medline].

  27. Torres VE, Harris PC. Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol. Jan 2006;2(1):40-55; quiz 55. [Medline]. [Full Text].

  28. Torres VE, Harris PC. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med. Jan 2007;261(1):17-31. [Medline].

  29. Schrier RW. Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology (Carlton). Apr 2006;11(2):124-30. [Medline].

  30. Patch C, Charlton J, Roderick PJ, Gulliford MC. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis. Jun 2011;57(6):856-62. [Medline].

  31. Russell RT, Pinson CW. Surgical management of polycystic liver disease. World J Gastroenterol. Oct 14 2007;13(38):5052-9. [Medline].

  32. Sallee M, Rafat C, Zahar JR, et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. Jul 2009;4(7):1183-9. [Medline].

  33. Doulton TW, Saggar-Malik AK, He FJ, Carney C, Markandu ND, Sagnella GA, et al. The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients. J Hypertens. May 2006;24(5):939-45. [Medline].

  34. Tahvanainen E, Tahvanainen P, Kääriäinen H, et al. Polycystic liver and kidney diseases. Ann Med. 2005;37(8):546-55. [Medline].

  35. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. Apr 14 2007;369(9569):1287-301. [Medline].

  36. Weimbs T. Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?. Cell Cycle. Nov 1 2006;5(21):2425-9. [Medline].

Previous
Next
 
Polycystic kidney.
Polycystic kidney disease and massive polycystic liver disease.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.